Actimmune interferon gamma-1b data

GNE said it will halt development of Actimmune for renal cell carcinoma as Phase III data have shown no clinical benefit. Two Phase III trials, one open-label, and one double-blinded and placebo-controlled, showed similar response rates, and the placebo-controlled trial showed no statistically significant difference in response rate or duration, time to progression, or survival. ...